Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
| Autor: | Jason E. Faris, Eli L. Diamond, Martina Makrutzki, Vivek Subbiah, Antoine Hollebecque, Maria Luisa Veronese, Maria Elena Elez-Fernandez, David M. Hyman, Radj Gervais, Juergen Wolf, Josep Tabernero, Igor Puzanov, Susan Frances Lasserre, Noopur Raje, Martin Schuler, Jean-Yves Blay, José Baselga, Emily Chan, Ian Chau, Ralf-Dieter Hofheinz, Florin Sirzen, Manuel Hidalgo, Antoine Italiano |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male Proto-Oncogene Proteins B-raf medicine.medical_specialty Indoles Colorectal cancer Medizin Antineoplastic Agents Article Internal medicine Carcinoma Non-Small-Cell Lung Neoplasms medicine Clinical endpoint Carcinoma Humans Lung cancer Vemurafenib Sulfonamides Cetuximab business.industry Cancer General Medicine medicine.disease Surgery Cohort Mutation Female business Histiocytosis medicine.drug |
| Popis: | BackgroundBRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. MethodsWe enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation–positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. ResultsIn the cohort with non–small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim–Chester disease or Langerhans’-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had diseas... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|